National Cancer Institute; Notice of Closed Meeting, 35684 [2019-15733]
Download as PDF
<![CDATA[
35684
Federal Register / Vol. 84, No. 142 / Wednesday, July 24, 2019 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS
NATIONAL STUDY
Number of
respondents
Form name
Total
responses
Average
burden per
response
(in hours)
Total
burden
hours
Grantee Recruitment ............................................................
Site Recruitment and Training .............................................
Patient Screening .................................................................
Patient Survey ......................................................................
220
700
13,120
9,058
1
1
1
1
220
700
13,120
9,058
2.00
3.15
.17
1.25
440.00
2,205.00
2,230.40
11,322.50
Total National Study .....................................................
23,098
........................
23,098
........................
16,197.90
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions; (2) the accuracy of the
estimated burden; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Maria G. Button,
Director, Division of the Executive Secretariat.
[FR Doc. 2019–15699 Filed 7–23–19; 8:45 am]
BILLING CODE 4165–15–P
[FR Doc. 2019–15733 Filed 7–23–19; 8:45 am]
National Institutes of Health
BILLING CODE 4140–01–P
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Feasibility
and Planning Studies for SPOREs to
Investigate Cancer Health Disparities (P20).
Date: September 25, 2019.
Time: 10:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
VerDate Sep<11>2014
16:53 Jul 23, 2019
Jkt 247001
7W618, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, 9609 Medical Center Drive, Room
7W618, National Cancer Institute, NIH,
Rockville, MD 20850, 240–276–6611,
mukesh.kumar3@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 19, 2019.
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
khammond on DSKBBV9HB2PROD with NOTICES
Number of
responses per
respondent
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections 552b(c)
(4) and 552b(c) (6), Title 5 U.S.C., as
amended. The purpose of this meeting
is to evaluate requests for preclinical
development resources for potential
new therapeutics for the treatment of
cancer. The outcome of the evaluation
will provide information to internal NCI
committees that will decide whether
NCI should support requests and make
available contract resources for
development of the potential
therapeutic to improve the treatment of
various forms of cancer. The research
proposals and the discussions could
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
JUN2019 Cycle 31 NExT SEP Committee
Meeting.
Date: August 8, 2019.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To evaluate the NCI
Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health,
9000 Rockville Pike, Building 35A,
Room 35, Bethesda, MD 20892.
Contact Persons: Barbara
Mroczkowski, Ph.D., Executive
Secretary, Discovery Experimental
Therapeutics Program, National Cancer
Institute, NIH, 31 Center Drive, Room
3A44, Bethesda, MD 20817, (301) 496–
4291, mroczkoskib@mail.nih.gov.
Toby Hecht, Ph.D., Executive
Secretary, Development Experimental
Therapeutics Program, National Cancer
Institute, NIH, 9609 Medical Center
Drive, Room 3W110, Rockville, MD
20850, (240) 276–5683, toby.hecht2@
nih.gov.
(Catalogue of Federal Domestic
Assistance Program Nos. 93.392, Cancer
Construction; 93.393, Cancer Cause and
Prevention Research; 93.394, Cancer
Detection and Diagnosis Research;
93.395, Cancer Treatment Research;
93.396, Cancer Biology Research;
93.397, Cancer Centers Support; 93.398,
Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of
Health, HHS)
Dated: July 19, 2019.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–15734 Filed 7–23–19; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\24JYN1.SGM
24JYN1
]]>Agencies
[Federal Register Volume 84, Number 142 (Wednesday, July 24, 2019)]
[Notices]
[Page 35684]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-15733]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Feasibility and Planning Studies for SPOREs to Investigate
Cancer Health Disparities (P20).
Date: September 25, 2019.
Time: 10:00 a.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W618, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Mukesh Kumar, Ph.D., Scientific Review Officer,
Research Program Review Branch, Division of Extramural Activities,
9609 Medical Center Drive, Room 7W618, National Cancer Institute,
NIH, Rockville, MD 20850, 240-276-6611, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: July 19, 2019.
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2019-15733 Filed 7-23-19; 8:45 am]
BILLING CODE 4140-01-P
